Here's a classic biotech story: a company gets a new drug approved, launches it, and starts to see prescriptions roll in. The commercial numbers look promising, but the stock price... well, that's a different conversation. That's the scene at Tonix Pharmaceuticals Holding Corp. (TNXP) right now.

The company reported its fourth-quarter and full-year 2025 results, and the headline is the early traction for Tonmya, its fibromyalgia drug. Since hitting the market in November 2025 through February 2026, more than 1,500 healthcare providers have written a prescription. That's translated to roughly 2,500 patients starting treatment and a cumulative total of about 4,200 prescriptions. For a drug that just launched a few months ago, that's not a bad start.

Tonmya is a big deal for the company because it's the first new prescription medicine approved for fibromyalgia in adults in over 15 years. Getting that FDA nod last August was the key that unlocked the commercial door. Now, the focus is on making sure patients can actually get it, which means convincing insurance companies to pay for it. Tonix says it's prioritizing expanding payer engagement, working on contracts with commercial insurers, and having discussions with Medicare and Medicaid.

Financially, it's a bit of a mixed bag. The company's sales for the quarter came in at $5.39 million, which almost doubled the consensus estimate of $2.88 million. That's the good news. The not-so-good news is that Tonix reported a fourth-quarter loss of $3.98 per share, which was wider than the $3.16 loss analysts were expecting.

To fund this commercialization push and other pipeline work, the company recently completed a $20 million registered direct offering with Point72 Asset Management. More importantly, Tonix says it's sitting on a healthy pile of cash—approximately $207.6 million in cash and equivalents as of the end of last year. Management believes that war chest is enough to support operations into the first quarter of 2027, which gives them a decent runway to keep pushing Tonmya and developing other drugs.

Now, let's talk about the stock, because that's where things get interesting. Despite the positive prescription numbers and the cash balance, the stock's technical picture looks... challenged. As of this reporting, Tonix is trading 5.2% below its 20-day simple moving average and a more significant 18.7% below its 100-day average. That generally indicates a bearish trend over the short to medium term. Over the past year, shares are down about 1.69% and are hanging out closer to their 52-week lows than their highs.

For the chart watchers, the Relative Strength Index (RSI) is at 36.03, which is considered neutral territory—not oversold, not overbought. The MACD indicator, however, is at -0.6454 with a signal line at -0.6704. Because the MACD is slightly above the signal line, it's hinting at a potential bullish crossover, which could mean some upward momentum might be brewing. Key resistance to watch is at $14.50, with support down at $12.80.

Market data signals show weak momentum for the stock, with a score indicating it's underperforming the broader market. The takeaway for investors seems to be a note of caution: the company's underlying product story is developing positively, but the market isn't fully buying into the equity story just yet. Investors will need to watch how prescription growth continues and whether the company can successfully navigate its payer negotiations to turn early adoption into sustained revenue.

Tonix Pharmaceuticals shares were up 1.12% at $13.56 in premarket trading on Friday.